Table 3 Descriptive characterization of pharmacophenotypes by medication class
| Â | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
MRC-ICU drugs | 36 (97.3) | 33 (100.0) | 45 (95.7) | 35 (100.0) | 44 (95.7) | 391 (97.3) |
Average weight value of MRC-ICU drugs | 1.2 (0.6) | 1.4 (0.7) | 1.3 (0.7) | 1.4 (0.7) | 1.2 (0.6) | 1.3 (0.7) |
MRC-ICU weight of 1 | 29 (78.4) | 22 (66.7) | 32 (68.1) | 25 (71.4) | 33 (71.7) | 288 (71.6) |
MRC-ICU weight of 2 | 3 (8.11) | 7 (21.2) | 9 (19.1) | 5 (14.3) | 7 (15.2) | 61 (15.2) |
MRC-ICU weight of 3 | 3 (8.1) | 3 (9.1) | 4 (8.5) | 5 (14.3) | 2 (4.3) | 36 (9.0) |
Analgesic | 5 (13.5) | 4 (12.1) | 6 (12.8) | 4 (11.4) | 4 (8.7) | 49 (12.2) |
Antiarrhythmics | 1 (2.7) | 2 (6.1) | 2 (4.2) | 1 (2.9) | 0 (0) | 18 (4.5) |
Antibiotic | 9 (24.3) | 4 (12.1) | 11 (23.4) | 9 (25.7) | 13 (28.3) | 98 (24.3) |
Anticoagulant | 3 (8.1) | 0 (0) | 3 (6.4) | 2 (5.7) | 2 (4.3) | 36 (8.9) |
Anticonvulsants | 0 (0) | 0 (0) | 1 (2.1) | 3 (8.6) | 1 (2.2) | 8 (2.0) |
Antidotes/rescue | 2 (5.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (1.0) |
Antifungal agents | 0 (0) | 1 (3.0) | 1 (2.1) | 1 (2.9) | 2 (4.3) | 7 (1.7) |
Antihypertensive | 2 (5.4) | 2 (6.1) | 0 (0) | 1 (2.9) | 2 (4.3) | 7 (1.7) |
Antiplatelet | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2.2) | 1 (0.2) |
Antiprotozoal agent | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (0.5) |
Antipsychotic | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.2) |
Antiviral agent | 0 (0) | 2 (6.1) | 1 (2.1) | 0 (0) | 0 (0) | 12 (3.0) |
COPD/asthma | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (0.5) |
Chemotherapy | 2 (5.4) | 1 (3.0) | 0 (0) | 0 (0) | 0 (0) | 2 (0.5) |
Diabetic agent | 1 (2.7) | 1 (3.0) | 0 (0) | 1 (2.9) | 1 (2.2) | 14 (3.5) |
Diuretic | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2.2) | 3 (0.7) |
Factor product | 0 (0) | 0 (0) | 1 (2.1) | 0 (0) | 0 (0) | 0 (0) |
Fluids | 4 (10.8) | 1 (3.0) | 4 (8.5) | 1 (2.9) | 0 (0) | 21 (5.2) |
Gastrointestinal | 0 (0) | 2 (6.1) | 3 (6.4) | 1 (2.9) | 4 (8.7) | 14 (3.5) |
Gastric agents | 1 (2.7) | 1 (3.0) | 1 (2.1) | 1 (2.9) | 1 (2.2) | 11 (2.7) |
Hypertonic saline | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (1.0) |
Immunosuppressant | 0 (0) | 1 (3.0) | 1 (2.1) | 0 (0) | 4 (8.7) | 9 (2.2) |
Intropic agent | 0 (0) | 1 (3.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Laxative | 0 (0) | 0 (0) | 1 (2.1) | 0 (0) | 0 (0) | 2 (0.5) |
Neuromuscular blocking agent | 0 (0) | 2 (6.1) | 2 (4.2) | 0 (0) | 0 (0) | 11 (2.7) |
Opioid reversal | 0 (0) | 0 (0) | 1 (2.1) | 1 (2.9) | 0 (0) | 1 (0.2) |
Sedative agents | 1 (2.7) | 5 (15.1) | 4 (8.5) | 4 (11.4) | 3 (6.5) | 27 (6.7) |
Somatostatic agents | 1 (2.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (1.0) |
TPN | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2.2) | 3 (0.7) |
Vasoactive agent | 0 (0) | 1 (3.0) | 0 (0) | 0 (0) | 1 (2.2) | 2 (0.5) |
Vasodilator | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.2) |
Vasopressor | 5 (13.5) | 2 (6.1) | 3 (6.4) | 5 (14.3) | 5 (10.9) | 28 (6.9) |
Drug indicates critical illness (always) | 12 (32.4) | 13 (39.4) | 7 (14.9) | 11 (31.4) | 11 (23.9) | 91 (22.6) |
Drug indicates critical illness (maybe) | 17 (45.9) | 11 (33.3) | 22 (46.8) | 17 (48.6) | 21 (45.7) | 189 (47.0) |
Intravenous route | 27 (73.0) | 22 (66.7) | 29 (61.7) | 25 (71.4) | 30 (65.2) | 253 (62.9) |
Route escalation | 20 (54.1) | 17 (51.6) | 20 (42.6) | 23 (65.7) | 12 (26.1) | 182 (45.3) |